Peer-reviewed veterinary case report
Immunotherapy with tumor antigen microbeads for dogs with B-cell
By Henson, M S et al.·Published in Veterinary and comparative oncology·2011·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma.
- Species:
- dog
Plain-English summary
Five dogs with untreated B-cell lymphoma were given a new treatment involving special microbeads made from their own tumor cells, along with two immune-boosting substances, IL-2 and GM-CSF. After having their lymph nodes removed and receiving initial chemotherapy, the dogs were vaccinated with this new therapy. The good news is that there were no serious side effects, and half of the dogs showed a positive immune response to the treatment. While this study focused on safety, it suggests that this approach could help dogs with lymphoma in the future.
People also search for: dog lymphoma treatment options · B-cell lymphoma in dogs · immunotherapy for dogs with cancer
Abstract
Cytotoxic T-lymphocyte responses to subcellular antigens are enhanced when antigens are presented on cell-sized silica microbeads called large multivalent immunogens (LMIs). LMIs prepared with tumour cell membrane fragments have induced partial remissions in humans with melanoma and renal cell carcinoma. The purpose of this phase I study was to evaluate the safety of LMIs, prepared with autologous lymphoma cell membranes, along with subcutaneous interleukin 2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) in dogs with untreated B-cell lymphoma. After lymph node excision and induction chemotherapy, five dogs were vaccinated with three weekly doses of LMI alone; five with LMI and subcutaneous IL-2 and five with LMI, IL-2 and GM-CSF. No significant toxicity was noted, treatment did not adversely affect disease-free interval and half of the dogs showed measurable delayed-type hypersensitivity reactions to intradermal challenge with LMI, suggesting specific cell-mediated immunity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21569195/